3D bioprinted retina tissue uncovers advanced age-related macular degeneration
Medgadget - 06-Jan-2023Researchers are making strides in developing advanced in vitro tissue models to study eye diseases
Join the club for FREE to access the whole archive and other member benefits.
Head of the Ocular and Stem Cell Translational Research Section at NEI.
Ocular and Stem Cell Translational Research Section
NEI
Building 10, Room 10B10,10 Center Drive,Bethesda,MD-20892
301-451-9372
Dr. Bharti holds a bachelor's degree in biophysics from the Panjab University in Chandigarh, India, where he graduated with highest honors. This was followed by a master degree in biotechnology at the Maharaja Sayaji Rao University in Baroda, India and a diploma in molecular cell biology at the Johann Wolfgang Goethe University at Frankfurt in Germany. Supported by an international Ph.D. student fellowship, he obtained his Ph.D. from the same institution, graduating summa cum laude. His Ph.D. work involved basic biology in the areas of heat stress, cellular chaperones, and epigenetics. From Germany, Dr. Bharti came to the National Institute of Neurological Disorders and Stroke to work with Dr. Heinz Arnheiter as a postdoctoral fellow. While there, he published numerous papers in the areas of transcription factor regulation, pigment cell biology, and the developmental biology of the eye. It is perhaps this combination of diverse backgrounds that led him to develop an interest in the emerging field of stem cell biology, particularly of the retinal pigment epithelium, as he moved into the role of staff scientist. Dr. Bharti has authored numerous publications and has won several awards, including, most recently, being a finalist in the prestigious trans-NIH Earl Stadtman Symposium.
Visit website: https://irp.nih.gov/pi/kapil-bharti
See also: National Eye Institute (NEI) - Performs and supports vision research and education programs
Details last updated 16-Apr-2020
Researchers are making strides in developing advanced in vitro tissue models to study eye diseases
Fast, cheap and plentiful iPSCs will be needed for clinical trials and new treatments
Challenges of mass producing stem cells and how 3 companies are attempting to overcome them
Researchers plan clinical trials of this in humans to treat retinal diseases
Patient-derived induced pluripotent stem cells to replace dead retinal cells